Phase 3 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study and are willing to sign a written consent form.
• People aged 18 to 80 years old.
• People with a general health and activity level rated as fairly good (rated 0–2 on a standard scale used by doctors to measure how cancer affects daily life).
• People whose pancreatic cancer has spread to other parts of the body (metastatic) and has been confirmed by laboratory testing of tissue or cells as adenocarcinoma (a specific type of pancreatic cancer).
• People whose blood test results show that major organs such as the liver and kidneys are working well enough.
• People who have at least one area of cancer that can be measured on a scan, according to standard medical guidelines.
• People whose haemoglobin (a measure of red blood cells) is at an acceptable level (8 g/dL or above).
• People whose expected survival is at least 3 months.
• People who are able to commit to using effective contraception throughout the study (applies to women who could become pregnant and to men).

Who may not be able to join:

• People who have received cancer treatment for a different type of cancer within the last two years.
• People who have previously received any cancer treatment for pancreatic cancer.
• People whose cancer has been confirmed by laboratory testing as a type of pancreatic cancer other than adenocarcinoma.
• People who have inflammation of the digestive tract, such as pancreatitis (inflamed pancreas), cholecystitis (inflamed gallbladder), or cholangitis (inflamed bile ducts).
• People who are pregnant or currently breastfeeding.
• People who have a condition called G6PD deficiency, which is an inherited condition affecting red blood cells.
• People with serious uncontrolled health conditions that could interfere with the study, including uncontrolled infections, diabetes that cannot be managed with standard treatment, uncontrolled high blood pressure, certain heart conditions (such as severe heart failure, a heart attack in the past 6 months, unstable heart rhythm, or unstable chest pain), or a stroke within the past 3 months.
• People with kidney disease or who are currently on dialysis.
• People with a history of serious allergic reactions to gemcitabine, nab-paclitaxel, or similar medicines used in this study.
• People with other serious health conditions that, in the treating doctor's judgement, could make treatment unsafe.
• People who are unwilling or unable to follow the study procedures.

Important: Always verify eligibility with the trial site directly before applying.